Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Diluted Average) (2022 - 2025)

Stoke Therapeutics has reported Shares Outstanding (Diluted Average) over the past 4 years, most recently at $59.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $59.2 million for Q4 2025, up 9.65% from a year ago — trailing twelve months through Dec 2025 was $59.2 million (up 9.65% YoY), and the annual figure for FY2025 was $59.2 million, up 9.65%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $59.2 million at Stoke Therapeutics, down from $60.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for STOK hit a ceiling of $60.4 million in Q3 2025 and a floor of $37.4 million in Q1 2022.
  • Median Shares Outstanding (Diluted Average) over the past 4 years was $45.3 million (2023), compared with a mean of $48.7 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 28.59% in 2024 and later rose 7.02% in 2025.
  • Stoke Therapeutics' Shares Outstanding (Diluted Average) stood at $38.9 million in 2022, then rose by 13.1% to $44.0 million in 2023, then increased by 22.76% to $54.0 million in 2024, then rose by 9.65% to $59.2 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $59.2 million (Q4 2025), $60.4 million (Q3 2025), and $59.7 million (Q2 2025) per Business Quant data.